One type thermal ablation appeared superior for cT1 a renal cell carcinoma patients.
Patients with cT1a renal cell carcinoma (RCC) have better overall survival if they receive treatment with cryoablation instead of heat-based thermal ablation, a study found.
Jing Wu, MD, of Second Xiangya Hospital, Central South University, Changsha, Hunan, China, andcolleagues studied 6258 patients with cT1a RCC: 3936 treated with cryoablation and 2322 treated with heat-based thermal ablation. After propensity score matching, the cryoablation group had significantly longer median overall survival than the patients treated with heat-based thermal ablation (11.3 vs 10.4 years), the researchers reported in the Journal of Vascular and Interventional Radiology.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.